Literature DB >> 1373735

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

C Grunfeld1, M Pang, W Doerrler, J K Shigenaga, P Jensen, K R Feingold.   

Abstract

Infection causes disturbances in lipid metabolism that may be mediated by cytokines. Therefore we studied plasma lipids, lipoproteins, triglyceride (TG) metabolism, and serum cytokines in three groups: patients with the acquired immunodeficiency syndrome (AIDS) without active secondary infection, patients with evidence of human immunodeficiency virus infection but without clinical AIDS (HIV+), and controls. Plasma TGs and FFA were increased in AIDS, while plasma cholesterol, high density lipoprotein (HDL) cholesterol, apolipoprotein-A-1 (Apo-A-1), low density lipoprotein (LDL) cholesterol, and Apo-B-100 levels were decreased. Increased TG levels in AIDS were primarily due to increases in very low density lipoprotein of normal composition; in addition, LDL and HDL were TG enriched. In HIV+, TGs and FFA were not increased, but total cholesterol, HDL cholesterol, Apo-A-1, and Apo-B-100 were significantly decreased. Interferon-alpha (IFN alpha) and C-reactive protein levels were increased in AIDS, but tumor necrosis factor and haptoglobin levels were not. There was a significant correlation between plasma TGs and IFN alpha levels (r = 0.477; P less than 0.01), but not between TGs and tumor necrosis factor, C-reactive protein, haptoglobin, or P-24 antigen. In addition, there was no relationship between circulating IFN alpha levels and plasma cholesterol, HDL cholesterol, Apo-A-1, LDL cholesterol, Apo-B-100, or FFA. TG clearance time and postheparin lipase were significantly decreased in AIDS and HIV+. There was a strong correlation between serum IFN alpha levels and TG clearance time in AIDS and HIV+ (r = 0.783; P less than 0.001). In summary, decreases in cholesterol and cholesterol containing lipoproteins (including HDL) in both AIDS and HIV+ precede the appearance of hypertriglyceridemia and are not related to IFN alpha or TG levels. Our data raise the possibility that with development of AIDS, subsequent increases in IFN alpha may contribute to increases in plasma TG levels in part by decreasing the clearance of TG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373735     DOI: 10.1210/jcem.74.5.1373735

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  223 in total

1.  Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

Authors:  K M Wasan; F W Strobel; S C Parrott; M Lynn; W J Christ; L D Hawkins; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 2.  Dyslipidemia and its Treatment in HIV Infection.

Authors:  Carl Grunfeld
Journal:  Top HIV Med       Date:  2010 Aug-Sep

3.  Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Madhu N Rao; Grace A Lee; Carl Grunfeld
Journal:  Am J Infect Dis       Date:  2006-09-30

Review 4.  An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.

Authors:  Christine B Bruno; Jeffrey M Schapiro; Parya Saberi
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2011-04-25

Review 5.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

Review 6.  Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice.

Authors:  Enrico Cerrato; Fabrizio D'Ascenzo; Giuseppe Biondi-Zoccai; Pierluigi Omedè; Claudio Moretti; Stefania Cicalini; Gurumurthy Parthasarathi; Imad Sheiban; Fiorenzo Gaita
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

Review 7.  Insulin resistance in HIV-related lipodystrophy.

Authors:  Nasser Mikhail
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study.

Authors:  Michelle C Odden; Rebecca Scherzer; Peter Bacchetti; Lynda Anne Szczech; Stephen Sidney; Carl Grunfeld; Michael G Shlipak
Journal:  Arch Intern Med       Date:  2007-11-12

9.  Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.

Authors:  Itziar Frades; Ben Readhead; Letizia Amadori; Simon Koplev; Husain A Talukdar; Heidi M Crane; Paul K Crane; Jason C Kovacic; Joel T Dudley; Chiara Giannarelli; Johan L M Björkegren; Inga Peter
Journal:  Circ Genom Precis Med       Date:  2019-05-06

10.  Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Authors:  Ighovwerha Ofotokun; Lumine H Na; Raphael J Landovitz; Heather J Ribaudo; Grace A McComsey; Catherine Godfrey; Francesca Aweeka; Susan E Cohn; Manish Sagar; Daniel R Kuritzkes; Todd T Brown; Kristine B Patterson; Michael F Para; Randi Y Leavitt; Angelina Villasis-Keever; Bryan P Baugh; Jeffrey L Lennox; Judith S Currier
Journal:  Clin Infect Dis       Date:  2015-03-12       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.